Citations

Clear

9383 citation(s) found for "Thomas, PS".

Transcranial doppler (TCD) in predicting outcomes following successful mechanical thrombectomy of large vessel occlusions in anterior circulation: a systematic review and meta-analysis
Jazayeri, Seyed Behnam , Pirahanchi, Yasaman , Ravi, Vikas , Carrión‐Penagos, Julián , Bowers, Jeffrey, Modir, Royya , Agrawal, Kunal , Hemmen, Thomas , Meyer, Brett C. , Meyer, Dawn , Sabayan, Behnam , Bowers, Jeffrey, Agrawal, Kunal, Shahripour, Reza Bavarsad , Agrawal, Kush

Mayo Clinic

Journal of NeuroInterventional Surgery | October 18, 2024 | Volume: 17 | Issue: 12 | Pages: 1325-1332

10.1136/jnis-2024-022457 | PMID 39424305 Get It

Background Transcranial Doppler (TCD) is a non-invasive, bedside tool that allows for real-time monitoring of the patient’s hemodynamic status following mechanical thrombectomy (MT). This systematic review and meta-analysis aims to evaluate the predictive value of TCD parameters following successful MT (Thrombolysis in Cerebral Infarction 2b–3). Methods In July 2024, we searched PubMed, Embase, and Scopus, to identify observational studies in which TCD parameters were measured within 48 hours of MT. Using random-effects models, we compared four TCD parameters (mean flow velocity (MFV), MFV index, pulsatility index (PI), and peak systolic velocity (PSV) among groups with vs without hemorrhagic transformation (HT) and favorable vs poor functional recovery (modified Rankin Scale 0–2 vs 3–6). Results Eleven studies comprising 1432 patients (59% male; mean age range: 63–73 years) were included. The MFV and MFV index were higher in patients with HT (Hedges' g=0.42 and 0.54, P=0.015 and 0.005, respectively). Patients with MFV index ≥1.3 showed a higher risk of all HT (RR 1.97; 95% confidence interval (CI) 1.28 to 3.03, P=0.002), symptomatic HT (RR 4.68; 95% CI 1.49 to 14.65, P=0.008), and poor functional status at 90 days (RR 1.65; 95% CI 1.27 to 2.14, P=0.029), respectively. There was no difference in mean PSV (P=0.1) and PI (P=0.3) among groups with and without HT. Conclusion This study underscores the prognostic value of the MFV index in predicting HT, symptomatic HT, and poor functional recovery after successful MT in the anterior circulation. Large-scale, multi-center studies are necessary to confirm these findings and to validate the MFV index as a reliable predictor for improving post-thrombectomy care.
P12.09.A EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA
Hanft, Simon , Elder, B L, Giglio, Pierre , Wu, Siqi , Farrell, Christopher , Alnahhas, Iyad , Lee, I-Y., Walbert, Tobias , Boockvar, John A. , Aregawi, Dawit , Kim, L., Schulder, Michael , Singer, S, Correia, Carlos Eduardo Silva , Ramakrishna, Rohan , Jeyapalan, Suriya, Magge, Rajiv , Agarwal, Vijay , Amankulor, N, Quinones-Hinojosa, A, Neese, Laura L., Scott, Charles , Pérez‐Ollé, Raül, Andrews, David , Lee, Ian , Lee, Ian Y , Elder, B, Lee, I Y, Vojnic, Morana , Zacharia, Brad E. , Kim, L., Ghatan, Saadi , Wu, J, Patel, Nitesh V. , Bhatia, Ankush , Brennan, Cameron , Evans, L, Gill, B, Sengupta, Soma , Wong, Eric T. , Amankulor, N, Quinones-Hinojosa, A, Andrews, D

Mayo Clinic

Neuro-Oncology | October 17, 2024 | Volume: 26 | Issue: Supplement_5 | Pages: v67-v68

10.1093/neuonc/noae144.222 Get It

Abstract BACKGROUND Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. Imvax has utilized its Goldspire™ platform to create IGV-001, an autologous biologic-device combination product for the treatment of newly diagnosed GBM (ndGBM). IGV-001 consists of autologous GBM tumor cells and an antisense oligonucleotide against IGF-1R mRNA (IMV-001), irradiated and administered via biodiffusion chambers implanted in the abdomen. Together, these components stimulate immunogenic cell death and antigen release. In a phase 1b study in patients with ndGBM, IGV-001 was well tolerated without unexpected adverse events. Multiple efficacy signals were also observed, including significant improvements in progression-free survival, overall survival, radiographic evidence of tumor response, and changes in immune response biomarkers. A phase 2b randomized, multicenter, double-blind, placebo-controlled study to assess the safety and efficacy of IGV-001 in patients with ndGBM (ClinicalTrials.gov identifier: NCT04485949) is ongoing. Here, we present the first safety data from the study. MATERIAL AND METHODS After surgical resection, patients are treated with IGV-001 or placebo followed by SOC. The study will enroll approximately 93 patients at 20 sites in the United States, with a 2:1 randomization favoring IGV-001. The primary outcome is progression-free survival, defined as the time from randomization to first progression, as determined by blinded central radiology review, or death. Secondary outcomes include overall survival, defined as the time from randomization to death due to any cause, and safety. RESULTS As of February 2, 2024, a total of 72 patients have been randomized and 69 have been implanted with IGV-001 or placebo plus SOC. The median age was 60.0 years (range, 24-70 years). Most randomized patients (76.4%) were 51-70 years of age, and the male:female ratio was 2.27. A total of 39/45 (86.7%) patients with enough follow-up time, initiated treatment with concurrent radiation and temozolomide. A total of 9/72 (12.5%) randomized patients discontinued treatment, including 7 patients who discontinued during the SOC treatment period. No patients discontinued treatment for adverse events, protocol deviations, or death. A total of 11/72 (15.3%) randomized patients discontinued the study after randomization. CONCLUSION To date, the review of blinded safety data did not show any emerging risk and supports that there is no change to the benefit-risk profile of treatment with IGV-001 versus placebo. The data will be updated before presentation.
Identification of patients on chronic prescription opioids at risk for opioid use disorder using pharmacy claims data
Jantzen, Aleesha, Hall, Scott T. , Cunningham, Julie L. , Odell, Laura, Hall, Scott Thomas , Lai, Benjamin , Lai, Benjamin

Mayo Clinic

Journal of Healthcare Risk Management | October 17, 2024 | Volume: 44 | Issue: 2 | Pages: 14-19

10.1002/jhrm.21585 | PMID 39418134 Get It

AbstractUsing pharmacy claims data from a single commercial health plan to identify opportunities for opioid use disorder (OUD) focused screening and interventions communicated via targeted prescriber messaging. Participants included members ≥18 years using more than 90 morphine milligram equivalents (MMED) daily based on all opioid claims, had >1 paid claim for an opioid product, and had ≥90 days of total opioid therapy. Members were excluded with ≥1 claims for an oral chemotherapy agent (except methotrexate). Intervention was completed with a secure communication to the primary outpatient opioid prescriber that included resources for diagnosis, treatment, and best practices for opioid prescribing. The main outcome measure was any documented change to opioid use following the intervention. Seven hundred forty‐five members were identified; a subset (n = 20) was further assessed, and all had identified OUD risk factors; providers were subsequently sent a communication. Sixteen providers acknowledged receipt and 11 patients (55%) had at least one documented intervention following communication receipt. Provision of targeted, evidence‐based recommendations to providers for patients identified to be at risk of OUD from pharmacy claims data can result in increased recognition and intervention. Future efforts to explore feasibility of provider education detailing efforts and continued evaluation of efficacy are needed.
Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma
Gile, Jennifer , Maurer, Matthew J. , Ruan, Gordon , Abeykoon, Jithma P. , Heimgartner, Joy , Baumann, N, McMahon, Molly, Gile, Jennifer Jane , Maurer, Matthew , Ruan, Gordon J , Heimgartner, Joy R, Baumann, Nikola A, Lin, Yi , Witzig, Thomas E.

Mayo Clinic

The Oncologist | October 17, 2024 | Volume: 29 | Issue: 12 | Pages: e1779-e1782

10.1093/oncolo/oyae255 | PMID 39418117 Get It

Abstract Magnesium (Mg) is an essential element involved in cellular metabolism. We demonstrated that in patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (SCT), those with a serum Mg < 2.0 mg/dL at the time of transplant had worse outcomes. In this study, we aimed to learn the prognostic value of low serum Mg in patients with untreated DLBCL. We analyzed serum from 408 patients and tested 2 Mg cutpoints—low (<1.7 mg/dL) and low normal (<2.0 mg/dL), a range we found associated with lower survival in the SCT group. We found 3% of patients with low levels and 23% with low normal levels. Low normal serum Mg levels were associated with a higher stage at diagnosis, more extranodal involvement, higher international prognostic index score, lower overall survival (OS), and event-free survival. These data warrant testing Mg replacement to a target of >2.0 mg/dL to learn if survival can be improved.
Vesalius and His Manikin: An Enduring Influence on Modern Anatomic Teaching
On, Thomas J. , Xu, Yuan , Jubran, Jubran H. , Castillo, Andrea L. , Alcantar-Garibay, Oscar, Dagi, Teo Forcht, Preul, Mark C., Meybodi, Ali Tayebi

Mayo Clinic

Neurosurgery | October 17, 2024 | Volume: 96 | Issue: 2 | Pages: 235-250

10.1227/neu.0000000000003187 | PMID 39813067 Get It

Anatomic teaching has long informed surgical knowledge, experience, and skills. One tool for teaching that emerged during the Renaissance was the fugitive anatomic sheet, which used flap layers to reveal different levels of anatomy. In 1538, Vogtherr introduced the first fugitive sheets, which included illustrations of male and female figures with a torso paper flap that, when lifted, revealed the internal organs in a cartoonish style. The popularity of these anatomic fugitive sheets spurred an increase in small print-and-sale workshops. In 1543, Vesalius included fugitive anatomic sheets in his books Fabrica and Epitome , containing large paper flapped models that could be created by cutting out and gluing images of human internal anatomy onto a base layer. Students could tack these manikins up to a nearby wall during dissection. Significant collaboration between Vesalius and his publisher occurred to coordinate the integration of large foldable sheets featuring the cutout models into his works. Vesalius's groundbreaking discoveries, his use of the most advanced printing techniques, and his innovative teaching style are fundamental aspects of the legacy of medical education. This article shows these remarkable fugitive anatomic sheets from the original publications of Fabrica and Epitome together for the first time. It explores the innovative concepts and applications of Vesalius's unique printings.
Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity
Lyu, Yu-Xuan, Wilczok, Dominika , Antebi, Adam , Vojta, Aleksandar , Stolzing, Alexandra , Moskalev, Alexey , Georgievskaya, Anastasia , Maier, Andrea B. , Olsen, Andrea, Groth, Anja , Brunet, Anne , Jamil, Aisyah, Kulaga, Anton , Bhatti, A.R., Yaden, Benjamin C., Djordjevic, Boris, Chen, Chieh, Huang, Christine Yuan, Chen, Danica , Sołdacki, Dariusz, Meyer, David H. , Chini, Eduardo N. , Morgen, Eric , Vernet, Erik , Pinilla, Estefano, Mercken, Evi M. , Finger, Fabian , Kuipers, Folkert , Gyülvészi, Gábor, Zmudze, Garri, Blander, Gil , Pincus, Harold A., McClure, Joshua, Kirkland, James L. , Peyer, James , McLaughlin, Jerry L., Mannick, Joan B. , Betts-LaCroix, Joe , Sedivy, John M. , Speakman, John R. , Shlain, Jordan, Maltzahn, Julia von , Andreasson, Katrin I. , Moody, Kelsey , Fortney, Kristen , Niedernhofer, Laura J., Veenhoff, Liesbeth M. , Melton, Lisa , Quarta, Marco , Koval, Maria, Marinova, Maria B., Hamalainen, Mark, Unfried, Maximilian , Ringel, Michael S. , Filipović, Miloš R. , Topors, Mourad, Mitin, Natalia , Roy, N. N., Pintar, Nika, Barzilai, Nir , Binetti, Paolo, Kohlhaas, Paul, Rubin, Paul , Kamya, Petrina, Muñoz‐Cánoves, Pura , Конрад, Р. , Ripa, Roberto , Mansukhani, Robin, Büttner, Sabrina , Brunemeier, Sebastian, Jakimov, Sergey, Rosenzweig‐Lipson, Sharon, Tsai, Shih‐Yin , Rando, Thomas A. , Peterson, Timothy R. , Woods, Tina , Wyss‐Coray, Tony , Finkel, Toren , Strauss, Tzipora , Longo, Valter D. , Sorrentino, Vincenzo , Sebastiano, Vittorio , Li, Wenbin , Suh, Yousin , Niedernhofer, Laura J. , Lu, Yuxuan , Passos, Joao, Niedernhofer, Laura J , Wyss-Coray, Tony , Bakula, Daniela , Lyu, Yu-Xuan, Fu, Qiang , Ying, Kejun , King, Aaron, Olsen, Andrea, Simon, Anna Katharina , Jamil, Aisyah, Bhatti, Asif, Pedersen, Bente Klarlund , Schumacher, Björn , Kennedy, Brian Keith , Huang, Christine Yuan, Correll, Christoph Ulrich , Murphy, Coleen Tara , Ewald, Collin Y. , Valenzano, Dario Riccardo , Erritzøe, David , Sinclair, David , Teeling, Emma C. , Verdin, Eric , Pinilla, Estéfano , Fang, Evandro Fei , Bischof, Evelyne Y. , Pun, Frank W. , Civiletto, Gabriele , Justice, Jamie N. , Vijg, Jan , Gruhn, Jennifer R. , McLaughlin, Jerry, Passos, João F. , Baur, Joseph A. , Shlain, Jordan, Palikaras, Konstantinos , Rasmussen, Lene Juel , Ferrucci, Luigi , Koval, Maria, Topors, Mourad, Roy, Nawal, Pintar, Nika , Singh, Parminder Pal , Robbins, Paul D. , Fedichev, Peter O. , Cabo, Rafael de , Faragher, Richard , Konrad, Rob, Wickström, Sara A. , Brunemeier, Sebastian A., Luo, Shan , Dimmeler, Stefanie , Gladyshev, Vadim N. , Dwaraka, Varun B. , Gorbunova, Vera , Acosta-Rodríguez, Victoria A. , Suh, Yousin , Zhavoronkov, Alex , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | October 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.18632/aging.206135 | PMID 39418098 Get It

Polygenic risk scores stratify breast cancer risk among women with benign breast disease
Sherman, Mark E. , Winham, Stacey J. , Vierkant, Robert A. , McCauley, Bryan M. , Scott, Christopher G. , Schrup, Sarah E. , Gaudet, Mia M. , Troester, Melissa A. , Pruthi, Sandhya , Bolla, Manjeet K. , Wang, Qin , Dennis, Joe, Chang‐Claude, Jenny , Obi, Nadia, Aronson, Kristan J. , García‐Closas, Montserrat , Yang, Xiaohong R. , Pharoah, Paul D.P., Easton, Douglas F., Vachon, Celine M, Schrup, Sarah, Radisky, Derek C. , Wang, Qin , Dennis, Joe , Michailidou, Kyriaki , Truong, Therese , Obi, Nadia , Aronson, Kristan J , García-Closas, Montserrat , Chanock, Stephen Jacob , Yang, Xiaohong R , Mavaddat, Nasim , Easton, Doug , Vachon, Celine M. , Winham, Stacey J , Vierkant, Robert A , Scott, Christopher , Gaudet, Mia M , Sherman, Mark E , Degnim, Amy C. , Couch, Fergus J. , Michailidou, Kyriaki , Guénel, Pascal , Truong, Thérèse , Murphy, Rachel A. , Ahearn, Thomas U. , Dunning, Alison M. , Easton, Douglas F.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 16, 2024 | Volume: 117 | Issue: 3 | Pages: 456-464

10.1093/jnci/djae255 | PMID 39412492 Get It

Abstract Background Most breast biopsies are diagnosed as benign breast disease, with 1.5- to 4-fold increased breast cancer risk. Apart from pathologic diagnoses of atypical hyperplasia, few factors aid in breast cancer risk assessment of these patients. We assessed whether a 313–single nucleotide variation (formerly single-nucleotide polymorphism) polygenic risk score stratifies risk of benign breast disease patients. Methods We pooled data from 5 Breast Cancer Association Consortium case-control studies (mean age = 59.9 years), including 6706 participants with breast cancer and 8488 participants without breast cancer. Using logistic regression, we estimated breast cancer risk associations by self-reported benign breast disease history and strata of polygenic risk score, with median polygenic risk score category among women without benign breast disease as the referent. We assessed interactions and mediation of benign breast disease and polygenic risk score with breast cancer risk. Results Benign breast disease history was associated with increased breast cancer risk (odds ratio [OR] = 1.48, 95% confidence interval [CI] = 1.37 to 1.60; P < .001). Polygenic risk score increased breast cancer risk, irrespective of benign breast disease history (Pinteraction = .48), with minimal evidence of mediation of either factor by the other. Women with benign breast disease and polygenic risk score in the highest tertile had more than twofold increased odds of breast cancer (OR = 2.73, 95% CI = 2.41 to 3.09), and those with benign breast disease and polygenic risk score in the lowest tertile experienced reduced breast cancer risk (OR = 0.79, 95% CI = 0.70 to 0.91) compared with the referent group. Women with benign breast disease and polygenic risk score in the highest decile had a 3.7-fold increase (95% CI = 3.00 to 4.61) compared with those with median polygenic risk score without benign breast disease. Conclusion Breast cancer risks are elevated among women with benign breast disease and increase progressively with polygenic risk score, suggesting that optimal combinations of these factors may improve risk stratification.
Cryoablation for unresectable unicentric Castleman disease
Nishimura, Yoshito , Atwell, Thomas D. , Callstrom, Matthew R. , Howard, Matthew T., King, Rebecca L. , Atwell, Thomas, Callstrom, Matthew, McGarrah, Patrick , Howard, Matthew, Dispenzieri, Angela , Nishimura, Yoshito , McGarrah, Patrick W. , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | October 16, 2024 | Volume: 100 | Issue: 1 | Pages: 149-151

10.1002/ajh.27507 | PMID 39411984 Get It

Defining Echocardiographic Degrees of Right Heart Size and Function in Pulmonary Vascular Disease From the PVDOMICS Study
Mukherjee, Monica , Mathai, Stephen C. , Jellis, Christine , Freed, Benjamin H. , Yanek, Lisa R. , Agoglia, Hannah , Chiu, Caitlin , Jani, Vivek , Simpson, Catherine E. , Park, Margaret , Beck, Gerald J. , Hill, Nicholas S. , Erzurum, Serpil C. , Thomas, James D. , Kwon, Deborah , Kim, Jiwon , Group, the PVDOMICS Study, Mathai, Stephen C , Simpson, Catherine E , Freed, Benjamin H , Mukherjee, Monica , Brittain, Evan L , Tang, W.H. Wilson , Hemnes, Anna R. , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , Hassoun, Paul M. , Leopold, Jane A. , Horn, Evelyn M. , Group, the PVDOMICS Study

Mayo Clinic

Circulation: Cardiovascular Imaging | October 15, 2024 | Volume: 17 | Issue: 10 | Pages: No page available

10.1161/circimaging.124.017074 | PMID 39691460 Get It

BACKGROUND: Defining qualitative grades of echocardiographic metrics of right heart chamber size and function is critical for screening, clinical assessment, and measurement of therapeutic response in individuals with pulmonary vascular disease (PVD). In a population enriched for PVD, we sought to establish qualitative grades and prognostic value of right heart chamber size and function. METHODS: We investigated 1053 study participants in PVDOMICS (Redefining Pulmonary Hypertension Through the PVD Phenomics Program) to determine clinical and echocardiographic differences associated with increasing pulmonary vascular resistance severity. Right heart chamber size and function were qualitatively assessed using a percentile-based approach above the median values to create a clinical grading system for right heart adaptation. The relationship between echocardiographic categories and all-cause mortality was examined using survival analyses adjusted for potential confounders. RESULTS: A stepwise increase in adverse right heart remodeling was observed with a concomitant decrease in functional parameters by pulmonary vascular resistance strata ( P <0.001 for all). Mild, moderate, and severe categories of right heart chamber size and dysfunction were defined using a percentile-based approach across the spectrum of PVD. During a median follow-up of 2.07 years (interquartile range, 1.23–3.01 years), 130 participants died (11.4%). Progressive pulmonary vascular resistance increase and 2DE evidence of right heart dysfunction inclusive of fractional area change, and right ventricular global longitudinal strain were independently associated with increased all-cause mortality risk in multivariate analysis adjusted for age, disease duration, and male sex. CONCLUSIONS: In this well-characterized sample of adults with diverse etiologies and varying PVD severity, we define categories of abnormal right heart chamber size and function. Further, we demonstrate a stepwise relationship between these categories of abnormal morphology and function and all-cause mortality. Defining grades of right ventricular dysfunction in individuals with known PVD has important clinical implications for monitoring disease progression and response to therapies.
Endovascular Treatment of Complex Aorto-Iliac Atherosclerotic Occlusive Disease With Chimney Covered Endovascular Reconstruction of Aortic Bifurcation
Dvir, May , Shuja, Fahad , Sen, Indrani , Gurrieri, Carmelina , Carmody, Thomas , Tallarita, Tiziano , Carmody, Thomas

Mayo Clinic

Vascular and Endovascular Surgery | October 14, 2024 | Volume: 59 | Issue: 3 | Pages: 331-337

10.1177/15385744241291083 | PMID 39400241 Get It

Treatment of atherosclerotic occlusive disease of the infrarenal aorta poses several challenges. Traditionally, open surgery has been the preferred method of treatment in standard risk patients, although, it is burdened by high morbidity and mortality. There are many classifications to establish the patient risk for surgery. Among the most common is the American College of Cardiology (ACC)/American Heart Association (AHA) classification. ACC/AHA high-risk patients benefit from the increase in endovascular technology and skills. The treatment modality of atherosclerotic aortic disease has shifted towards a minimally invasive approach, including kissing stents, covered endovascular reconstruction of the aortic bifurcation (CERAB) and, aorto-uniiliac stent grafts. When there is an involvement of vital branches such as the inferior mesenteric (with concomitant occluded superior mesenteric artery) or the renal arteries, Chimney- CERAB technique has been successfully utilized to overcome this challenge. We present three patients with aortoiliac occlusive disease (AIOD) successfully treated with the chimney- CERAB technique to preserve a large inferior mesenteric artery in the setting of occlusion/near occlusion of the other mesenteric vessels.